A B S T R A C T
Background. The excessive accumulation of extracellular matrix (ECM) in the renal tubulointerstitium is a key component of chronic renal damage in lupus nephritis (LN) and a critical determinant of the disease progression to renal failure. Detection of fibrosis requires renal biopsy and is therefore limited by high risks associated with an invasive procedure. This study explores whether a unique LN urinary peptidome can be identified and whether LN-specific alteration reflects the underlying fibrogenic process of altered ECM turnover. Method. Urinary peptides were analyzed for 36 LN and 35 nonrenal systemic lupus erythematosus (SLE) subjects and 58 healthy volunteers (HVs). Results. In total, 70 collagen and 230 noncollagen peptides were significantly changed between LN and nonrenal SLE and between LN and HV and defined as 'LN peptides'; 14 proteases associated with observed LN collagen peptides were identified and activities in 9 proteases were significantly different between LN and nonrenal SLE; 28 collagen peptides were correlated with at least one parameter of clinical renal dysfunction or histolopathology. Conclusion. Urinary peptidomic alterations likely reflect pathogenic pathways involving ECM turnover in LN kidneys and potentially could be developed as biomarkers to monitor renal disease progression.
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I N T R O D U C T I O N
Lupus nephritis (LN) is a common and serious complication of systemic lupus erythematous (SLE) and a major cause of morbidity and mortality [1] . Up to 50% of adult patients with SLE have signs of renal involvement early in the course of the disease and may eventually develop overt renal disease. The clinical course of LN varies from mild subclinical disease to an aggressive course that may progress to end-stage renal failure. The pathogenesis of LN is complex, involving the underlying systemic activation of autoreactive B cells and formation of polyclonal autoantibodies, which are deposited in the renal glomeruli, where the Fc-mediated activation of macrophages and complement fixation subsequently result in immune complex-mediated injury and disease [2] . Through multiple mechanisms, including cell proliferation and the production of extracellular matrix (ECM) proteins, proinflammatory cytokines, chemokines and matrix metalloproteinases (MMPs), the initial glomerular injury extends to renal tubular damage, vascular injury, tubulointerstitial inflammation and fibrosis [3] [4] .
Fibrotic changes, as revealed by histologic features of fibrous crescents, tubular injury, tubulointerstitial inflammation and fibrosis, identify LN patients at the greatest risk for progression to renal failure [5] [6] [7] . In particular, tubulointerstitial fibrosis is among the strongest predictors of poor renal outcome in LN, as it leads to the reduction of functioning Nephrol Dial Transplant (2017) 32: 1468-1477 doi: 10.1093/ndt/gfw446 Advance Access publication 23 February 2017 renal mass and the development of renal failure. However, the detection of fibrotic processes requires renal biopsy for histopathology or molecular profiling and is therefore limited by the risks associated with an invasive procedure. Clinical renal disease activity is monitored by proteinuria and serum creatinine (sCr) [2, [8] [9] [10] . While proteinuria is a sensitive and relevant measure of renal disease, it is poorly correlated with histologic measure, resulting in over-or undertreatment [11] . In addition, renal dysfunction measures such as sCr and estimated glomerular filtration rate (eGFR) are relatively insensitive, as dysfunction is only detected at the advanced stages of disease [12] . Better methods are sorely needed to detect fibrogenic processes occurring in LN kidney and thereby monitor disease progression and guide treatment decisions. Additionally, elucidation of the processes resulting in alterations in ECM turnover through altered expression and activity of ECM proteases and other fibrogenic mediators may suggest future therapeutic interventions.
Recently, a classifier based on 273 urinary peptides for the diagnosis of chronic kidney disease (CKD) of different origins was developed [13] . This so-called CKD273 classifier, generated by analysis of urinary peptides by capillary electrophoresis-mass spectrometry (CE-MS) using patients with various biopsy-proven kidney diseases and healthy volunteers (hereafter referred to as controls), included peptides from collagens, blood proteins, kidney-specific proteins and various secreted proteins. These 273 biomarkers were combined into one classifier using the support vector machine algorithm and validated in an independent test set, composed of mostly diabetic nephropathy (DN) patients, with sensitivity of 85.5% and specificity of 100% in discriminating CKD patients from controls. Further studies showed it also predicts the progression of DN [14, 15] . The authors used longitudinally collected samples and observed that the classifier was able to predict which patients develop DN during the average follow-up of 9 years. Schanstra et al. [16] recently investigated a cross-sectional cohort of 1990 samples from patients with different CKD. In this study, the CE-MS-detected urinary peptides found to be associated with CKD were either fragments of the major circulating proteins or collagen peptides. The latter were positively correlated with eGFR, suggesting reduced collagen degradation and hence increased intrarenal ECM deposition. As expected, there was a substantial overlap (73%) between the peptides defined by Schanstra et al. and included in the CKD273 classifier.
To date, there has been limited analysis of urinary peptide profiles of LN patients, and these have not been compared with SLE patients without renal involvement (nonrenal SLE) to identify signals attributable to the renal disease. The aim of our study was to explore whether the levels of urinary peptides including potential markers of altered ECM turnover were changed in LN as compared with nonrenal SLE and controls and to determine their correlations with clinical renal disease parameters. This analysis would thereby advance the potential development of LN biomarkers to reflect key fibrogenic processes in the kidney underlying disease progression.
M A T E R I A L S A N D M E T H O D S

Study population
In total, 129 subjects (36 LN, 35 nonrenal SLE and 58 controls) were selected from three different sources. All 35 nonrenal SLE and 18 LN subjects were selected from the Study of Biological Pathways, Disease Activity and Response Markers in Patients with Systemic Lupus Erythematosus (SPARE), approved by the Johns Hopkins Institutional Review Board with the consent of individuals and funded by the National Institutes of Health (AR043727). The remaining 18 LN subjects and 19 controls were selected from NCT01731054, a prospective noninterventional study evaluating magnetic resonance imaging (MRI) in LN subjects. The remaining 39 control samples were from Bioreclamation (Baltimore, MD, USA). LN, nonrenal SLE and control subjects were matched for age, gender and race. sCr, urine protein:creatinine ratio (uPCR) and eGFR were obtained for all subjects. The physicians' global assessment (PGA), renal SLE disease activity index (rSLEDAI) and global SLEDAI (gSLEDAI) were obtained for nonrenal SLE and LN subjects from SPARE. The biopsy total activity index (AI) and total chronicity index (CI) were obtained for 18 LN subjects from NCT01731054 as previously described [17] .
LN subjects from the SPARE longitudinal cohort were selected based on prior renal biopsy and current disease activity evidenced by at least two of the following criteria: (i) uPCR >0.5 mg/mg, (ii) sCr >1.1 mg/dL and (iii) rSLEDAI !4. LN subjects from NCT01731054 were selected based on their levels of proteinuria (uPCR >1.0 mg/mg) within 30 days of enrollment and demonstration of activity in the biopsy performed within 7 days of enrollment. A total of four LN subjects were protocol deviations and enrolled with uPCR <1.0 mg/mg. Nonrenal SLE subjects were selected with similar nonrenal SLE activity and no historical or current renal involvement measured by PGA, rSLEDAI, uPCR and sCr.
Sample processing and analysis
Midstream spot urine samples collected from study subjects were centrifuged (1500 g, 15 min) before the supernatant was decanted and frozen at À20 C or À70 C. Peptide analysis was performed as previously described [18, 19] . Briefly, aliquots of 0.7 mL were thawed and diluted with 0.7 mL of 2 M urea, 10 mM NH 4 OH and 0.02% SDS, then proteins were filtered out using 20-kDa Centrisart devices (Sartorius, Germany) and desalted using a PD-10 column (GE Healthcare, Sweden), lyophilized and stored at 4 C, followed by reconstitution and analysis on a CE-MS platform. Mass spectral ion peaks were processed using MosaiquesVisu software [20] . Migration time and signal intensity were normalized using 'internal polypeptide standards' [21] . Peptides were sequenced on a nanoLC-MS/MS platform [22] . Data were searched against the human International Protein Index (version 3.87) using Proteome Discoverer [no enzyme, no fixed modification, oxidation of methionine and proline as variable modifications, mass error at 10 ppm (MS) and 0.05 Da (MS/MS)]. Peptide identities were further validated by CE-MS/MS analysis and the strict correlation of peptide charge with CE migration time [23] .
Statistical analysis
Sample demographics were compared by an analysis of variance test followed by a Tukey test. Detected, identified and validated peptides in at least four samples were included in the data analysis. Peptide levels across groups were compared by the Kruskal-Wallis test followed by the Dunn test. BenjaminiHochberg adjustment was used for multiple testing. Statistical significance was set at an adjusted P-value <0.05. Correlation was performed using Spearman's rank analysis. The analyses were performed using R.
In silico protease mapping
A combination of Proteasix and MEROPS was used to generate possible proteases for LN peptides [24, 25] . For each protease-cleavage site (CS) combination, a confidence level of high, medium or low was assigned. If the protease-CS combination is experimentally observed in the Proteasix databases, such mapping is assigned as 'high confidence'; if not, prediction based on available MEROPS binding affinities of proteases to amino acid sequences was used to derive confidence levels as previously described [26] . Those predicted with high confidences and with three or more CS associations are considered as proteases responsible for observed LN peptides. For a given protease, its activity in a subject was calculated as the mean intensity of all associated peptides. The protease activity was compared by Mann-Whitney test with P < 0.05 for statistical significance.
R E S U L T S
Urine samples were obtained from 36 LN subjects at one time point of active disease and from 35 nonrenal SLE subjects and 58 controls. Subject characteristics are reported in Table 1 . The clinical parameters correspond to the time point of urine sampling for peptide analysis. The elevated gSLEDAI in the LN group was mainly due to the renal contribution since the PGA was not statistically different from the nonrenal SLE group.
A total of 1577 peptides were detected in urine samples. Of these, 778 collagen peptides corresponded to 26 types of collagen proteins, with the majority of peptides derived in order of abundance from type I, III, IV, V and II ( Figure 1 ).
LN peptides
There were 487 peptides, including 182 collagen peptides, significantly different in the pair-wise comparisons among LN, nonrenal SLE and controls (data not shown). The LN peptides, defined as those significantly different between LN and nonrenal SLE and between LN and controls, included 300 (70 collagen and 230 noncollagen) peptides.
Of 70 LN collagen peptides, 62 were mapped to the four most abundant collagen proteins (COL1A1, COL1A2, COL3A1 and COL18A1), while the remaining 8 mapped to six other collagen proteins (Table 2 ; Supplementary Figure S1 ). Notably, for all four abundant proteins, peptides changed in both directions in LN versus controls. For example, for COL1A1 peptides, 21 were decreased and 9 increased, and for COL3A1 peptides, 10 Continued L u p u s n e p h r i t i s u r i n a r y p e p t i d e s Where a reference is given, it indicates an association to CKD was reported and the peptide was changed in the same direction in CKD versus controls, unless indicated, as in LN versus nonrenal SLE and HV in this study. Table S1 ).
In silico protease identification
To obtain molecular pathway information underlying LN, we expanded analyses to predict enzymes potentially responsible for generation of the 300 LN peptides. Three peptides were not associated to any protease and were omitted in the analysis. A total of 73 proteases were predicted for 297 LN peptides and 22 were considered as proteases responsible for generating 47 collagen and 47 noncollagen peptides (Table 3; Supplementary Table  S2) . Notably, MMP9 and MMP13 were associated with 34 and 25 collagen peptides, respectively, and cathepsin D (CTSD) could be responsible for 25 noncollagen peptides.
Given our interest in mechanisms leading to ECM alterations, protease activities in LN and nonrenal SLE were subsequently analyzed for 14 collagen-associated proteases (Table 3) on the LN collagen peptides. The results, shown as log2-fold change in the mean activity in LN or nonrenal SLE subjects relative to that of controls (Figure 2 ), revealed significant differences between LN and nonrenal SLE in nine proteases, with increased activities of cathepsin B (CTSB); MMP1, 3, 7, 9, 14 and 20 and decreased activities of MMP2 and tripeptidyl-peptidase 1 (TPP1) in LN subjects relative to controls.
Correlation of LN peptides with clinical/histologic assessments
We next correlated the 300 LN peptides to six clinical or histologic parameters in LN subjects. These included sCr, eGFR, uPCR, rSLEDAI, AI and CI. Due to limited available clinical and biopsy data, correlation analysis to rSLEDAI was performed in the LN subjects from SPARE and correlation analysis to AI and CI was performed in the LN subjects from NCT01731054. The results showed that 173, including 28 collagen peptides, have moderate to strong correlation (jrj ! 0.5) to at least one parameter (Supplementary Table S3 ). Specifically, 137, 47, 19, 17, 16 and 7 peptides were correlated to AI, rSLEDAI, eGFR, sCr, uPCR and CI, respectively. All increased collagen peptides except one exhibited positive correlation to AI, rSLEDAI, uPCR, CI and sCr and negative correlation to eGFR. The converse was observed for the decreased collagen peptides (Table 4 ) and noncollagen peptides exhibited the same correlation patterns (Supplementary Table S4 ).
D I S C U S S I O N
The pathogenesis of LN involves autoantibody deposition in the kidney, immune complex-mediated renal injury and induction of proinflammatory pathways, which can ultimately result in progressive tissue fibrosis. We hypothesized that fibrogenic processes, including alterations in ECM turnover in LN kidneys, could be informed by changes in the urinary peptidome. In this study we identified a significantly different urinary peptide profile in LN as compared with that of controls. The LN profile notably included alterations in 70 collagen and 230 noncollagen peptides. Molecular pathways underlying LN were informed by in silico assessment predicting enzymes likely responsible for cleavage of the kidney-expressed proteins. We also report correlations of LN peptides with clinical assessments for renal dysfunction and, for the first time to our knowledge, with renal biopsy activity index, indicating that altered ECM turnover is occurring in conjunction with renal inflammation in LN.
In this study we analyzed the urinary collagen peptide alterations in LN patients and proteases predicted to be responsible for their generation. Of 70 LN collagen peptides identified, 36 were reduced and 34 increased in LN versus controls. A pattern of both increased and decreased peptides from a single protein was observed for COL1A1, COL1A2, COL3A1 and COL18A1, suggesting altered proteolytic cleavage of these abundant collagen proteins. Our in silico assessment pointed to 14 proteases associated with 47 LN collagen peptide generation, and 9 of them have altered protease activities in LN. Two of these (MMP7 and MMP14) were reported to have upregulated mRNA levels in tubules and glomeruli in LN kidney, [27] , consistent with our observation of their increased protease activity. We then looked further at the protein expression in kidney. Of these 14 proteases, we found 11 [CTSB, MMP2, 3, 7, 9, 13, 14, 20, neprilysin (MME), prolyl endopeptidase (PREP) and TPP1] expressed in the kidney, and MME appears to be kidney specific [28] . Notably, MMP13 associated to 25 collagen peptides was only found in kidney and colon out of 60 evaluated human tissues [28] , and MMP20 associated to 9 collagen peptides was found only in kidney among 17 evaluated tissues [29] . Moreover, of the 10 LN peptidemapped collagen proteins, 8 (COL1A1, COL1A2, COL3A1, COL4A3, COL4A5, COL12A1, COL18A1 and COL23A1) are expressed in kidney, with COL18A1 having the highest expression [28, 29] . These findings strongly support that the alterations in urinary collagen fragments reflect local proteolytic events (ECM turnover) and therefore informs fibrogenic processes in LN kidneys. Two LN peptide-mapped collagen proteins (COL2A1 and COL11A2) have not been reported as present in the kidney. However, COL2A1 has been found in urinary bladder [29] and COL11A2 was detected in urine [28] . The three LN peptides from COL2A1 and COL11A2 were increased in urine. This may reflect the LN-associated changes in organs peripheral to the kidney and/or changes in the bladder or urine.
To determine whether there were collagen peptide alterations unique to LN, we compared the results in LN (this study) with those reported in CKD patients of different etiologies [13, 16] . Among the 36 LN downregulated peptides, we identified 10 and 23 were also decreased in CKD in the two studies cited above, respectively. The overlap in the decreased collagen peptides in LN and CKD patients versus controls supports that similar dysregulation in ECM turnover underlies LN and other CKD. Notably, of 36, 9 were uniquely identified in LN and 2 (each from COL1A1 and COL3A1) were decreased in LN but increased in CKD patients. In contrast, there is very small overlap in the increased peptides. Only 3 of the 34 increased collagen peptides were reported to be upregulated in CKD [13] , thus 31 were uniquely identified in LN subjects. The identification of these unique LN peptides suggests that there may be pathological processes unique to ECM turnover in LN. The increase in LN peptides is unlikely a consequence of increased glomerular permeability, as analyzed peptides are so small (<20 kDa) that they are expected to be freely filtered and hence should not be influenced by glomerular permeability. Additionally, we observed both up-and downregulated LN peptides, indicating that altered glomerular permeability does not simply explain the observed changes in abundance of small peptides. We further identified 12 proteases likely responsible for generating 19 of these 31 unique LN peptides. Three of these, MME, MMP2 and PREP, were not implicated for any peptide increased in both CKD and LN. These results suggest that differential protease activities are featured in LN as compared with other CKDs. Further study is needed to confirm unique and/or differentiated protease activities in LN and to elucidate the unique pathology underlying LN.
To assess the potential use of the altered peptides as biomarkers, correlation analysis of the 300 LN peptides to six selected clinical or biopsy parameters was performed. Of 173 LN peptides showing moderate to strong correlation, 98, including 12 collagen peptides, have been previously reported to be associated with CKD [13, 16] . Notably, of 19 peptides correlated to eGFR in this study, 16, including 2 collagen peptides, were correlated to baseline or the slope of eGFR in all or advanced CKD patients [16] . Thus our study in LN patients is in agreement with prior findings in CKD showing that there are urinary peptide alterations correlating with renal dysfunction, i.e. increased proteinuria is positively correlated with upregulated peptides and reduced eGFR is positively correlated with downregulated peptides in LN. It is worth mentioning that of 240 increased LN peptides (34 collagen and 210 noncollagen), only 13 were correlated with uPCR. The fact that most LN peptides were not correlated with uPCR further argues that the increase in LN peptides is unlikely to have resulted from increased glomerular permeability and was likely caused by altered proteolysis. Moreover, our study found correlations of 137 LN peptides to AI and 7 to CI, including 22 and 1 collagen peptides, respectively. AI and CI are composite scores derived from fibrosisinforming histologic features; six (glomerular endocapillary hypercellularity, leukocyte infiltration, fibrinoid necrosis/karyorrhexis, cellular crescents, subendothelial hyaline deposits and interstitial inflammation) were used in AI and four (glomerular sclerosis, fibrous crescents, tubular atrophy and interstitial fibrosis) were used in CI score formation. The correlation of altered collagen peptides with histologic AI is consistent with the notion that alterations in ECM turnover occur in sync with inflammation, suggesting the potential use of LN peptides to infer inflammatory activity in LN kidney, thereby influencing the course of therapy. Together with AI or CI, noncollagen peptides (discussed further below) have good potential as biomarkers reflecting renal pathology. While our biopsy study is based on a small LN cohort, it provides insight into significantly advancing identification of much needed biomarkers. It will be of great interest to determine how these urinary peptidomic changes reflect disease progression and histologic changes in the kidney.
In addition to collagen peptides, 230 noncollagen peptides were also significantly altered, mostly increased, in LN versus controls. Many of the mapped proteins, including alpha-1-antitrypsin, which comprised 47 of the 230 peptides, are plasma transporters and known proteinuria and/or inflammation biomarkers. Findings on these noncollagen proteins are in good agreement with previous studies of CKD subjects with reduced renal function [13, 16, 30] ; the increased urinary excretion of their fragments likely reflects chronic kidney damage. Nevertheless, 115 and 6 of these noncollagen peptides correlated with AI and CI, respectively. Thus noncollagen peptides may also be of value as biomarkers reflecting LN renal pathology. Moreover, the peptides mapped to sodium/potassiumtransporting ATPase subunit gamma (FXYD2) and uromodulin (UMOD), two kidney-specific proteins [28, 29, 31, 32] , are interesting. Three of four FXYD2 and two of five UMOD peptides are correlated to biopsy AI; the same two UMOD peptides and one FXYD2 peptide were also correlated to rSLEDAI. FXYD2 is a single ion transmembrane transporter found in the distal convoluted tubule in the kidney and basolateral membranes of nephron epithelial cells. It is known to be associated with hypomagnesemia 2 but has not yet been implicated in LN. We identified four FXYD2-derived LN peptides; all three decreased peptides (covering AA 2-18, 3-18 and 7-18, respectively) contain the sequence of the increased peptide (covering AA 9-18). As such, the increased peptide is likely the product of further degradation of those three peptides that are consequently decreased as a result of activation of a specific protease. Although predicted with low confidence, CTSB, an enzyme with altered mRNA level in LN kidneys [27] , was suggested to be responsible for generating the increased FXYD2 peptide and thereby points to CTSB activity as a local mechanism associated with LN. UMOD is a glycoprotein exclusively synthesized in renal tubular cells that facilitate neutrophil migration across renal epithelia. It is known to be involved in several kidney diseases but is implicated in LN in only one report to date [33] . We found five increased UMOD peptides, located in the C-terminal region 589-606, which overlaps with the region (586-607) involved in UMOD polymerization into filaments [32] . Our analysis predicts that MMP3, MMP9, kallikrein-2 and neutrophil elastase are responsible for generating these peptides, albeit with varying degrees of confidence. All of these proteases have been implicated in LN [34] [35] [36] [37] [38] [39] [40] ; our study linked them to protein substrates whose proteolysis may contribute to LN, extending prior findings of changed mRNA levels of particular enzymes in LN kidneys [27] . These results, together with observed changes in substrate-derived urinary peptides, further point to proteolysis as the pathological mechanism underlying renal disease in LN.
The potential use of urinary peptides as biomarkers of renal diseases, particularly ECM peptides, is a compelling prospect [41] since it would be an attractive complement to current methods of monitoring disease progression. Our study identifies alterations in urinary collagen and noncollagen peptides that correlate with renal biopsy AI and CI. We speculate that there is great potential in developing urinary peptides as LN biomarkers reflecting pathological processes, including fibrogenic events, underlying disease progression locally in the kidney and which would be useful for informing disease state and course of therapy.
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